<?xml version="1.0" encoding="UTF-8"?>
<p>Phase I, phase II, and phase III clinical trials on healthy volunteers and patients with Ebola virus infection asserted the pharmacokinetic properties and a safety profile of this compound (high human tolerance, no cytotoxicity, hepato- or renal toxicities, and no/reduced severe adverse effects were detected) [
 <xref rid="B31-jcm-09-02084" ref-type="bibr">31</xref>].
</p>
